Arcturus Therapeutics
ARCT
19 hedge funds and large institutions have $5.29M invested in Arcturus Therapeutics in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.85% more ownership
Funds ownership: 10.09% → 10.94% (+0.85%)
14% less funds holding
Funds holding: 22 → 19 (-3)
45% less capital invested
Capital invested by funds: $9.58M → $5.29M (-$4.28M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$448K |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$255K |
| 3 |
Morgan Stanley
New York
|
+$145K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$109K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$8.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$290K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$164K |
| 3 |
JP Morgan Chase
New York
|
-$148K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$16.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.49K |
ARCT Hedge Fund Activity: Q4 2018 in Review
19 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2018, worth a combined $5.29M — down 45% from $9.58M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ARCT and 3 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $448K. The largest seller was Worth Venture Partners, exiting entirely with an estimated $290K sold.
- 19 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2018, down from 22 in Q3 2018.
- Funds reported $5.29M of Arcturus Therapeutics stock for Q4 2018, down 45% quarter-over-quarter.
- 3 funds opened new Arcturus Therapeutics positions in Q4 2018 and 6 closed out, a net change of -3 holders.
- The largest Arcturus Therapeutics buyer in Q4 2018 was DAFNA Capital Management, an estimated $448K added.
- The largest Arcturus Therapeutics seller in Q4 2018 was Worth Venture Partners, an estimated $290K sold.
Based on aggregated 13F filings for Q4 2018.